Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism
of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.